Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Lund Univ, Skane Univ Hosp, Dept Clin Sci, Neurosurg, Lund, Sweden.;Lund Univ, Dept Clin Sci, Glioma Immunotherapy Grp, Neurosurg, Lund, Sweden..
Lund Univ, Dept Clin Sci, Glioma Immunotherapy Grp, Neurosurg, Lund, Sweden..
Lund Univ, Dept Clin Sci, Glioma Immunotherapy Grp, Neurosurg, Lund, Sweden..
Lund Univ, Dept Clin Sci, Glioma Immunotherapy Grp, Neurosurg, Lund, Sweden..
Show others and affiliations
2023 (English)In: BMC Neurology, E-ISSN 1471-2377, Vol. 23, no 1, article id 76Article in journal (Refereed) Published
Abstract [en]

Purpose

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (TMZ). Experimental studies suggest that antisecretory factor (AF), an endogenous protein with proposed antisecretory and anti-inflammatory properties, may potentiate the effect of TMZ and alleviate cerebral edema. Salovum is an egg yolk powder enriched for AF and is classified as a medical food in the European Union. In this pilot study, we evaluate the safety and feasibility of add-on Salovum in GBM patients.

Methods

Eight patients with newly diagnosed, histologically confirmed GBM were prescribed Salovum during concomitant radiochemotherapy. Safety was determined by the number of treatment-related adverse events. Feasibility was determined by the number of patients who completed the full prescribed Salovum treatment.

Results

No serious treatment-related adverse events were observed. Out of 8 included patients, 2 did not complete the full treatment. Only one of the dropouts was due to issues directly related to Salovum, which were nausea and loss of appetite. Median survival was 23 months.

Conclusions

We conclude that Salovum is safe to use as an add-on treatment for GBM. In terms of feasibility, adherence to the treatment regimen requires a determined and independent patient as the large doses prescribed may cause nausea and loss of appetite.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2023. Vol. 23, no 1, article id 76
Keywords [en]
Glioblastoma, Antisecretory factor, Novel treatments against glioblastoma, Salovum
National Category
Neurology Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-498443DOI: 10.1186/s12883-023-03119-4ISI: 000936860300001PubMedID: 36803465OAI: oai:DiVA.org:uu-498443DiVA, id: diva2:1743971
Funder
Lund UniversitySjöberg FoundationRegion SkåneEU, Horizon 2020, h2020-MSCA-Cofund-754299Available from: 2023-03-16 Created: 2023-03-16 Last updated: 2023-03-16Bibliographically approved

Open Access in DiVA

fulltext(1162 kB)164 downloads
File information
File name FULLTEXT01.pdfFile size 1162 kBChecksum SHA-512
f84faae8356d7c2877a1f63270f5395751a9dc88b180a68b922a08869ca04d7deabea995e3fc51b1969b7ffc374f092b9f4b9f225303f59060ec44a9a05b3d23
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Belting, Mattias

Search in DiVA

By author/editor
Belting, Mattias
By organisation
Neurooncology and neurodegenerationScience for Life Laboratory, SciLifeLab
In the same journal
BMC Neurology
NeurologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 164 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 61 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf